Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Liver Neoplasms 2Hemangiosarcoma 2Glioma 2Choriocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Astrocytoma 1Adult Solid Tumor 1Adenoma, Liver Cell 1

Interventions

Temozolomide 29Bevacizumab 15Radiotherapy 13antineoplaston AS 2-1 8antineoplaston A10 8Everolimus 7Radiation 6Erlotinib Hydrochloride 6Radiotherapy, Intensity-Modulated 5Lomustine 4veliparib 3palbociclib 3Vorinostat 3Sunitinib 3Radiotherapy, Conformal 3Magnetic Resonance Spectroscopy 3Carmustine 3Carboplatin 3temsirolimus 2selinexor 2poly ICLC 2etoposide phosphate 2cabozantinib 2Sirolimus 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Imatinib Mesylate 2Etoposide 2Donepezil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Astrocytoma × carotuximab × Clear all
NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡